Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.48% |
| Dec 31, 2025 | -28.65% |
| Sep 30, 2025 | -39.98% |
| Jun 30, 2025 | -21.39% |
| Mar 31, 2025 | -105.38% |
| Dec 31, 2024 | -16.93% |
| Sep 30, 2024 | -34.68% |
| Jun 30, 2024 | -18.51% |
| Mar 31, 2024 | -4.73% |
| Dec 31, 2023 | -17.55% |
| Sep 30, 2023 | -17.46% |
| Jun 30, 2023 | -38.03% |
| Mar 31, 2023 | 80.98% |
| Dec 31, 2022 | 22.13% |
| Sep 30, 2022 | 42.72% |
| Jun 30, 2022 | 35.19% |
| Mar 31, 2022 | 22.47% |
| Dec 31, 2021 | 89.58% |
| Sep 30, 2021 | 49.91% |
| Jun 30, 2021 | 50.92% |
| Mar 31, 2021 | 31.13% |
| Dec 31, 2020 | 123.86% |
| Sep 30, 2020 | 31.50% |
| Jun 30, 2020 | 14.68% |
| Mar 31, 2020 | -16.69% |
| Dec 31, 2019 | 22.26% |
| Sep 30, 2019 | 22.77% |
| Jun 30, 2019 | 20.68% |
| Mar 31, 2019 | 19.17% |
| Dec 31, 2018 | 26.63% |
| Sep 30, 2018 | 23.27% |
| Jun 30, 2018 | 20.55% |
| Mar 31, 2018 | 16.86% |
| Dec 31, 2017 | 17.61% |
| Sep 30, 2017 | 17.22% |
| Jun 30, 2017 | 28.64% |
| Mar 31, 2017 | 9.22% |
| Dec 31, 2016 | 37.45% |
| Sep 30, 2016 | 16.79% |
| Jun 30, 2016 | 10.31% |
| Mar 31, 2016 | -8.46% |
| Dec 31, 2015 | 41.27% |
| Sep 30, 2015 | 0.89% |